Search

Your search keyword '"Park, Sang-Yoon"' showing total 1,548 results
Start Over Author "Park, Sang-Yoon"
1,548 results on '"Park, Sang-Yoon"'

3. Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes.

Author

Meagher, Nicola S, Gorringe, Kylie L, Wakefield, Matthew, Bolithon, Adelyn, Pang, Chi Nam Ignatius, Chiu, Derek S, Anglesio, Michael S, Mallitt, Kylie-Ann, Doherty, Jennifer A, Harris, Holly R, Schildkraut, Joellen M, Berchuck, Andrew, Cushing-Haugen, Kara L, Chezar, Ksenia, Chou, Angela, Tan, Adeline, Alsop, Jennifer, Barlow, Ellen, Beckmann, Matthias W, Boros, Jessica, Bowtell, David DL, Group, for the AOCS, Brand, Alison H, Brenton, James D, Campbell, Ian, Cheasley, Dane, Cohen, Joshua, Cybulski, Cezary, Elishaev, Esther, Erber, Ramona, Farrell, Rhonda, Fischer, Anna, Fu, Zhuxuan, Gilks, Blake, Gill, Anthony J, Initiative, for the Australian Pancreatic Genome, Gourley, Charlie, Grube, Marcel, Harnett, Paul R, Hartmann, Arndt, Hettiaratchi, Anusha, Høgdall, Claus K, Huzarski, Tomasz, Jakubowska, Anna, Jimenez-Linan, Mercedes, Kennedy, Catherine J, Kim, Byoung-Gie, Kim, Jae-Weon, Kim, Jae-Hoon, Klett, Kayla, Koziak, Jennifer M, Lai, Tiffany, Laslavic, Angela, Lester, Jenny, Leung, Yee, Li, Na, Liauw, Winston, Lim, Belle WX, Linder, Anna, Lubiński, Jan, Mahale, Sakshi, Mateoiu, Constantina, McInerny, Simone, Menkiszak, Janusz, Minoo, Parham, Mittelstadt, Suzana, Morris, David, Orsulic, Sandra, Park, Sang-Yoon, Pearce, Celeste Leigh, Pearson, John V, Pike, Malcolm C, Quinn, Carmel M, Mohan, Ganendra Raj, Rao, Jianyu, Riggan, Marjorie J, Ruebner, Matthias, Salfinger, Stuart, Scott, Clare L, Shah, Mitul, Steed, Helen, Stewart, Colin JR, Subramanian, Deepak, Sung, Soseul, Tang, Katrina, Timpson, Paul, Ward, Robyn L, Wiedenhoefer, Rebekka, Thorne, Heather, Investigators, for the kConFab, Cohen, Paul A, Crowe, Philip, Fasching, Peter A, Gronwald, Jacek, Hawkins, Nicholas J, Høgdall, Estrid, Huntsman, David G, James, Paul A, Karlan, Beth Y, and Kelemen, Linda E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Rare Diseases, Cancer, Digestive Diseases, Genetics, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Female, Humans, Neoplasm Staging, Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Adenocarcinoma, Mucinous, Prognosis, Gastrointestinal Neoplasms, AOCS Group, Australian Pancreatic Genome Initiative, kConFab Investigators, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeAdvanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathologic and gene-expression data were analyzed to identify prognostic and diagnostic features.Experimental designDiscovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n = 333), mucinous borderline ovarian tumors (MBOT, n = 151), and upper GI (n = 65) and lower GI tumors (n = 55).ResultsInfiltrative pattern of invasion was associated with decreased overall survival (OS) within 2 years from diagnosis, compared with expansile pattern in stage I MOC [hazard ratio (HR), 2.77; 95% confidence interval (CI), 1.04-7.41, P = 0.042]. Increased expression of THBS2 and TAGLN was associated with shorter OS in MOC patients (HR, 1.25; 95% CI, 1.04-1.51, P = 0.016) and (HR, 1.21; 95% CI, 1.01-1.45, P = 0.043), respectively. ERBB2 (HER2) amplification or high mRNA expression was evident in 64 of 243 (26%) of MOCs, but only 8 of 243 (3%) were also infiltrative (4/39, 10%) or stage III/IV (4/31, 13%).ConclusionsAn infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confers an adverse prognosis and is upregulated in the infiltrative subtype, which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.

Published
2022

18. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Author

Coleman, Robert, Spirtos, Nick, Enserro, Danielle, Herzog, Thomas, Sabbatini, Paul, Armstrong, Deborah, Kim, Jae-Weon, Park, Sang-Yoon, Kim, Byoung-Gie, Nam, Joo-Hyun, Fujiwara, Keiichi, Walker, Joan, Casey, Ann, Alvarez Secord, Angeles, Rubin, Steve, Chan, John, DiSilvestro, Paul, Davidson, Susan, Cohn, David, Basen-Engquist, Karen, Huang, Helen, Brady, Mark, Mannel, Robert, and Tewari, Krishnansu

Subjects
Aged, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Carboplatin, Combined Modality Therapy, Cytoreduction Surgical Procedures, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Paclitaxel, Quality of Life, Reoperation, Survival Analysis
Abstract

BACKGROUND: Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube (ovarian) cancer is widely practiced but has not been evaluated in phase 3 investigation. METHODS: We randomly assigned patients with recurrent ovarian cancer who had received one previous therapy, had an interval during which no platinum-based chemotherapy was used (platinum-free interval) of 6 months or more, and had investigator-determined resectable disease (to no macroscopic residual disease) to undergo secondary surgical cytoreduction and then receive platinum-based chemotherapy or to receive platinum-based chemotherapy alone. Adjuvant chemotherapy (paclitaxel-carboplatin or gemcitabine-carboplatin) and use of bevacizumab were at the discretion of the investigator. The primary end point was overall survival. RESULTS: A total of 485 patients underwent randomization, 240 to secondary cytoreduction before chemotherapy and 245 to chemotherapy alone. The median follow-up was 48.1 months. Complete gross resection was achieved in 67% of the patients assigned to surgery who underwent the procedure. Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance was administered to 84% of the patients overall and was equally distributed between the two groups. The hazard ratio for death (surgery vs. no surgery) was 1.29 (95% confidence interval [CI], 0.97 to 1.72; P = 0.08), which corresponded to a median overall survival of 50.6 months and 64.7 months, respectively. Adjustment for platinum-free interval and chemotherapy choice did not alter the effect. The hazard ratio for disease progression or death (surgery vs. no surgery) was 0.82 (95% CI, 0.66 to 1.01; median progression-free survival, 18.9 months and 16.2 months, respectively). Surgical morbidity at 30 days was 9%; 1 patient (0.4%) died from postoperative complications. Patient-reported quality of life decreased significantly after surgery but did not differ significantly between the two groups after recovery. CONCLUSIONS: In this trial involving patients with platinum-sensitive, recurrent ovarian cancer, secondary surgical cytoreduction followed by chemotherapy did not result in longer overall survival than chemotherapy alone. (Funded by the National Cancer Institute and others; GOG-0213 ClinicalTrials.gov number, NCT00565851.).

Published
2019

21. Cytoreductive Surgery

Author

Lim, Myong Cheol, primary, Bristow, Robert E., additional, Kim, Se Ik, additional, Ha, Hyeong In, additional, and Park, Sang-Yoon, additional

Published
2022
Full Text
View/download PDF

28. Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors.

Author

Kim, Ji Hyun, Kim, Eun Taeg, Kim, Se Ik, Park, Eun Young, Park, Min Young, Park, Sang-Yoon, and Lim, Myong Cheol

Subjects
THERAPEUTIC use of antineoplastic agents, PREDICTIVE tests, RESEARCH funding, DEATH, ENZYME inhibitors, DYNAMICS, PROBABILITY theory, RETROSPECTIVE studies, CYTOREDUCTIVE surgery, DESCRIPTIVE statistics, RESEARCH, TUMOR antigens, OVARIAN epithelial cancer, PROGRESSION-free survival, CONFIDENCE intervals, PLATINUM, EVALUATION
Abstract

Simple Summary: Prior research has identified various prognostic markers in epithelial ovarian cancer (EOC), including BRCA mutation status and a response to platinum-based chemotherapy, to predict outcomes in patients undergoing PARP inhibitor maintenance therapy. The role of CA-125 elimination rate constant K (KELIM), although recognized as a prognostic indicator, has not been fully investigated. This study underscores the prognostic significance of KELIM, revealing that a favorable KELIM score significantly correlates with better PFS in patients treated with primary cytoreductive surgery (PCS) followed by PARP inhibitor therapy. It also shows that KELIM's predictive value varies with the timing of surgery, extending a different view of its utility in real-world practice. KELIM could be integrated into clinical decision-making processes, potentially informing future clinical guidelines and research into optimal treatment strategies for targeted use of PARP inhibitors in advanced EOC patients. Background: This multicenter retrospective study aimed to investigate the prognostic value of the CA-125 elimination rate constant K (KELIM) in EOC patients who received platinum-based chemotherapy followed by PARP inhibitors, in either upfront or interval treatment settings. Methods: Between July 2019 and November 2022, we identified stage III–IV EOC patients who underwent primary or interval cytoreductive surgery and received olaparib or niraparib. Individual KELIM values were assessed based on validated kinetics and classified into favorable and unfavorable cohorts. Results: In a study of 252 patients undergoing frontline maintenance therapy with olaparib or niraparib, favorable KELIM (≥1) scores were associated with a higher PFS benefit in the primary cytoreductive surgery (PCS) cohort (hazard ratio (HR) for disease progression or death 3.51, 95% confidence interval (CI); 1.37–8.97, p = 0.009). Additionally, within the interval cytoreductive surgery (ICS) cohort, a favorable KELIM score (≥1) significantly increased the likelihood of achieving complete resection following cytoreductive surgery, with 59.4% in the favorable KELIM group compared to 37.8% in those with unfavorable KELIM. Conclusions: A favorable KELIM score was associated with improved PFS in patients with advanced EOC undergoing PCS. Furthermore, in the ICS cohort, a favorable KELIM score increased the probability of complete cytoreduction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae

Author

Lim, Myong Cheol, Won, Young-Joo, Lim, Jiwon, Seo, Sang-Soo, Kang, Sokbom, Yoo, Chong Woo, Kim, Joo-Young, Oh, Jae Hwan, Bristow, Robert E, and Park, Sang-Yoon

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rehabilitation, Colo-Rectal Cancer, Uterine Cancer, Clinical Research, Digestive Diseases, Prevention, Cancer, Adult, Aged, Aged, 80 and over, Colon, Colorectal Neoplasms, Comorbidity, Endometrial Neoplasms, Female, Humans, Incidence, Middle Aged, Neoplasms, Second Primary, Rectum, Registries, Republic of Korea, Survival Analysis, Survivors, Second primary tumor, Endometrial cancer, Colon cancer, Hereditary, Korea, Lynch syndrome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeTo evaluate the incidence of colon cancer as a second primary cancer (CCSPC) and the survival outcomes of women with and without CCSPC after the diagnosis of endometrial cancer (EC).MethodsThe standardized incidence ratio (SIR) of CCSPC and survival outcomes of EC survivors with and without CCSPC were analyzed using data from January 1 1993 to December 31 2011, obtained from the Korea Central Cancer Registry.ResultsOf 14,797 EC survivors, 147 (0.99%) developed CCSPC after an average interval of 5.5 years. The SIR of CCSPC among EC survivors was 2.56, higher than that of colon cancer in the general population. The SIR of CCSPC was highest for the ascending (3.77), followed by the transverse (3.45), descending colon (2.06), and rectum (1.99). The risk of a proximal site of CCSPC was high, especially within 5 years after the diagnosis of EC in the ascending (SIR, 4.37) and transverse (4.91) colon, and in young survivors (

Published
2018

35. Final primary analysis in the original cohort of KGOG3046/TRU-D: a phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer

Author

Park, Junsik, primary, Lee, Jungbok, additional, Lim, Myong Cheol, additional, Kim, Byoung-Gie, additional, Kim, Jae-Weon, additional, Kim, Sunghoon, additional, Choi, Chel Hun, additional, Kim, Hee Seung, additional, Park, Sang Yoon, additional, and Lee, Jung-Yun, additional

Published
2024
Full Text
View/download PDF

36. Efficacy of Immune-Checkpoint Inhibitors Combined with Cytotoxic Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Systematic Review and Meta-Analysis

Author

Kim, Ji Hyun, primary, Han, Kyung Hee, additional, Park, Eun Young, additional, Kim, Eun Taeg, additional, Kim, Eun-Jung, additional, Tan, David Sp, additional, Lee, Jung-Yun, additional, Park, Sang-Yoon, additional, Lim, Myong Cheol, additional, and Fotopoulou, Christina, additional

Published
2024
Full Text
View/download PDF

38. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Author

Vergote, Ignace, Scambia, Giovanni, Park, Sang Yoon, Song, Yong Sang, Makarova, Yulia, Trinidad, Joshua, Ngan, Hextan Yuen Sheung, Bamias, Aristotelis, Aravantinos, Gerasimos, Nam, Joo-Hyun, Gorbunova, Vera, Krikunova, Ludmila, Bae, Duk-Soo, Arija, Jose Angel Arranz, Mirza, Mansoor Raza, Zamagni, Claudio, Papandreou, Christos, Raspagliesi, Francesco, Lisyanskaya, Alla, Benzaquen, Ana Oaknin, Tognon, Germana, Ortega, Eugenia, Herraez, Antonio Casado, Buscema, Joseph, Green, Andrew, Burger, Robert, Sakaeva, Dina, Sanchez, Andres Redondo, Ghamande, Sharad, King, Laurel, Petru, Edgar, Peen, Ulla, Takeuchi, Satoshi, Ushijima, Kimio, Martin, Antonio Gonzalez, Kamelle, Scott, Carney, Michael, Marth, Christian, Forget, Frédéric, Bentley, James, Sehouli, Jalid, Colombo, Nicoletta, Zola, Paolo, Kato, Hidenori, Fadeeva, Natalya, Gotovkin, Evgeny, Vladimirov, Vladimir, Marin, Margarita Romeo, Alia, Eva Guerra, Shahin, Mark, Bhoola, Snehalkumar, Tewari, Krishnansu, Anderson, Daniel, Honhon, Brigitte, Pelgrims, Joseph (Gino), Oza, Amit, Jimenez, Jesus Garcia-Donas, Hansen, Vincent, O'Malley, David, Benjamin, Ivor, Renard, Vincent, Van den Bulck, Heidi, Meier, Werner, Haenle, Claudia, Koumakis, Georgios, Yokota, Harushige, Popov, Vadim, Bradley, William, Wenham, Robert, Reid, Robert, McNamara, Donna, Friedman, Richard, Barlin, Joyce, Spirtos, Nicola, Chapman, Julia, Sevelda, Paul, Huizing, Manon, Lamot, Caroline, Goffin, Frédéric, Hondt, Lionel D, Covens, Allan, Spadafora, Silvana, Rautenberg, Beate, Reimer, Toralf, Möbus, Volker, Hilpert, Felix, Gropp-Meier, Martina, Savarese, Antonella, Pignata, Sandro, Verderame, Francesco, Mizuno, Mika, Takano, Hirokuni, Ottevanger, Petronella, Velasco, Andres Poveda, Palacio-Vazquez, Isabel, Law, Amy, McIntyre, Kristi, Teneriello, Michael, Fields, Abbie, Lentz, Samuel, Street, Daron, Schwartz, Benjamin, Mannel, Robert, Lim, Peter, Pulaski, Heather, Janni, Wolfgang, Zorr, Andreas, Karck, Ulrich, Cheng, Ashley Chi Kin, Sorio, Roberto, Gridelli, Cesare, Aoki, Daisuke, Oishi, Tetsuro, Hirashima, Yasuyuki, Boere, Ingrid, Ferrer, Esther Falco, Braly, Patricia, Wilks, Sharon, Lee, Christine, Schilder, Jeanne, Veljovich, Dan, Secord, Angeles, Davis, Kevin, Rojas-Espaillat, Luis, Lele, Shashikant, DePasquale, Stephen, Squatrito, Robert, Schauer, Christian, Dirix, Luc, Vuylsteke, Peter, Joosens, Eric, Provencher, Diane, Lueck, Hans-Joachim, Hein, Alexander, Burges, Alexander, Canzler, Ulrich, Park-Simon, Tjoung-Won, Griesinger, Frank, Gadducci, Angiolo, Alabiso, Oscar, Okamoto, Aikou, Sawasaki, Takashi, Saito, Toshiaki, Ibañez, Ana Herrero, Calomeni, Coralia, Spillman, Monique, Choksi, Janak, Taylor, Nicholas, Muller, Carolyn, Moore, David, DiSilvestro, Paul, Cunningham, Mary, Rose, Peter, Oppelt, Peter, Verhoeven, Didier, Graas, Marie-Pascale, Ghatage, Prafull, Tonkin, Katia, Kurzeder, Christian, Schnappauf, Benjamin, Müller, Volkmar, Schmalzrie, Hannah, Kalofonos, Haralambos, Bruzzone, Milena, Kroep, Judith, Diaz, Cristina Caballero, Garcia, Jeronimo Martinez, Polo, Susana Hernando, Garrison, Mitchell, Rocconi, Rodney, Andrews, Stephen, Bristow, Robert, McHale, Michael, Basil, Jack, Houck III, William, Bell, Maria, Cosin, Jonathan, Modesitt, Susan, Kendrick, James, Wade III, James, Wong, Cheung, Evans, Anthony, Buekers, Thomas, Vanderkwaak, Timothy, Ferriss, James, Darus, Christopher, DAndre, Stacy, Higgins, Robert, Monk, Bradley, Bakkum-Gamez, Jamie, DeMars, Leslie, Van Le, Linda, Puls, Larry, Trehan, Shruti, LaPolla, James, Michelson, Elizabeth Dickson, Merchant, Joseph, Peterson, Christopher, Reid, Gary, Seago, Donald, Zweizig, Susan, Gajewski, Walter, Panwalkar, Amit, Leikermoser, Rudolf, Bogner, Gerhard, Debruyne, Philip, D'hondt, Randal, Berteloot, Patrick, Kerger, Joseph, Biagi, James, Castonguay, Vincent, Welch, Stephen, Muhic, Aida, Heubner, Martin, Grischke, Eva-Maria, Rack, Brigitte, Fleisch, Markus, Lordick, Florian, Pectasides, Dimitrios, Ho, Wing Ming, Selvaggi, Luigi, Vasquez, Flavia Morales, Villanueva, William Orlando Brito, Alavez, Alejandro Molina, Kessels, Lonneke, Bertran, Ana Santaballa, Fernandez, Cesar Mendiola, Fabregat, Miguel Beltran, Del Prete, Salvatore, Elkas, John, Cecchi, Gary, Kumar, Pallavi, Huh, Warner, Messing, Mark, Karimi, Misagh, Kelley, Ann, Edraki, Babak, Mutch, David, Leiserowitz, Gary, Anderson, Jeanne, Lentz, Scott, Chambers, Setsuko, Morris, Robert, Waggoner, Steven, Gordon, Alan, Method, Michael, Johnson, Peter, Lord, Raymond, Drake, Janet, Sivarajan, Kulumani, Midathada, Madhu, Rice, Kristen, Wadsworth, Troy, Pavelka, James, Edwards, Robert, Miller, David Scott, Ford, Patricia Locantore, Hurteau, Jean, Bender, David, Schimp, Veronica, Creasman, William, Lerner, Rachel, Chamberlain, Donald, Kueck, Angela, McDonald, John, Malad, Salman, Robinson-Bennett, Bernice, Davidson, Susan, Krivak, Thomas, Lestingi, Timothy, Arango, Hector, Berard, Paul, Finkelstein, Karen, Gaur, Rakesh, Krasner, Carolyn, Ueland, Frederick, Talmage, Lance, Yamada, Seiko, Sutton, Gregory, Potkul, Ronald, Prasad-Hayes, Monica, Osborne, Janet, Celano, Paul, Thigpen, James, Sharma, Sudarshan, Schilder, Russell, Tammela, Jonathan, Kemeny, Mary, Brown, Amy, Eisenhauer, Eric, Williams, James, Rowland, Kendrith, Nahum, Kenneth, Burke, James, Dar, Zahid, Fleming, Nicole, Gibb, Randall, Guirguis, Alfred, Herzog, Thomas, John, Veena, Kumar, Santhosh, Kamat, Aparna, Kassar, Mohamad, Leitao, Mario, Levine, Lyuba, Mendez, Luis, Patel, Dhimant, Berry, Emily, Warshal, David, Wolf, Judith, Zarwan, Corrine, Collins, Yvonne, Spitzer, Gary, Miller, Brigitte, Einstein, Mark, O'Malley, David M, Van Calster, Ben, Park, Sang-Yoon, del Campo, Josep M, Wenham, Robert M, Covens, Al, Raza Mirza, Mansoor, Kroep, Judith R, Ma, Haijun, Pickett, Cheryl A, and Monk, Bradley J

Published
2019
Full Text
View/download PDF

39. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

Author

Pujade-Lauraine, Eric, Fujiwara, Keiichi, Ledermann, Jonathan A, Oza, Amit M, Kristeleit, Rebecca, Ray-Coquard, Isabelle-Laure, Richardson, Gary E, Sessa, Cristiana, Yonemori, Kan, Banerjee, Susana, Leary, Alexandra, Tinker, Anna V, Jung, Kyung Hae, Madry, Radoslaw, Park, Sang-Yoon, Anderson, Charles K, Zohren, Fabian, Stewart, Ross A, Wei, Caimiao, Dychter, Samuel S, and Monk, Bradley J

Published
2021
Full Text
View/download PDF

40. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial

Author

Youn, Jin Won, Hur, Soo-Young, Woo, Jung Won, Kim, Yong-Man, Lim, Myong Cheol, Park, Sang Yoon, Seo, Sang Soo, No, Jae Hong, Kim, Byoung-Gie, Lee, Jae-Kwan, Shin, So Jin, Kim, Kyungun, Chaney, Marya F, Choi, Yoon-Jeong, Suh, You Suk, Park, Jong Sup, and Sung, Young Chul

Published
2020
Full Text
View/download PDF

49. TP017/#812 A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)

Author

Kim, Ji Hyun, primary, Park, Boram, additional, Park, Jeong-Yeol, additional, Lee, Jung-Yun, additional, Chang, Suk-Joon, additional, Lee, Yoo Young, additional, Hong, Dae Gy, additional, Cho, Hyun Woong, additional, Song, Jae Yun, additional, Kim, Jung-Yun, additional, Park, Sang-Yoon, additional, and Lim, Myong Cheol, additional

Published
2023
Full Text
View/download PDF

50. TP018/#822 A randomized, multicenter, open-label phase III trial of hyperthermic intraperitoneal chemotherapy in platinum-resistant recurrent ovarian cancer

Author

Kim, Ji Hyun, primary, Park, Eun-Young, additional, Jeong, Dae Hoon, additional, Lee, Yoo Young, additional, Choi, Chel Hun, additional, Kim, Tae-Joong, additional, Chung, Hyun Hoon, additional, Lee, Taek Sang, additional, Lee, Shin Wha, additional, Park, Jeong-Yeol, additional, Lee, Sung Jong, additional, Jeon, Seob, additional, Kim, Ki Hyung, additional, Ha, Hyeong In, additional, Ko, Youngbok, additional, Lee, San-Hui, additional, Chang, Suk-Joon, additional, Park, Sang-Yoon, additional, and Lim, Myong Cheol, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results